Whitehawk Therapeutics, Inc. (WHWK)

Market Cap	73.45M
Revenue (ttm)	25.98M
Net Income (ttm)	-63.69M
Shares Out	46.78M
EPS (ttm)	-2.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,279
Open	1.530
Previous Close	1.540
Day's Range	1.530 - 1.580
52-Week Range	1.210 - 3.812
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2025

About WHWK

Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: WHWK
• Website: https://ir.whitehawktx.com

Financial Performance

In 2024, Whitehawk Therapeutics's revenue was $25.98 million, an increase of 6.69% compared to the previous year's $24.35 million. Losses were -$63.69 million, -3.15% less than in 2023.